Tech Company Financing Transactions

ViaCyte Funding Round

ViaCyte closed a $25 million Series C venture capital round on 7/16/2007. Backers included Johnson & Johnson Development Corporation, Asset Management Ventures and Pacific Horizon Ventures.

Transaction Overview

Company Name
ViaCyte
Announced On
7/16/2007
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series C
Investors

Johnson & Johnson Development Corporation (Lead Investor)

Asset Management Ventures

Pacific Horizon Ventures

Sanderling Ventures (Fred Middleton)

Proceeds Purpose
Alan J. Lewis, President, ChiefExecutive Officer and Director of Novocell said, 'Future milestones include thepreclinical development of our diabetes cell therapy, enhancement of ourcancer stem cell program to create new therapies for cancer and thedevelopment of additional cell therapies based on our significant know-howand research expertise in this arena.'

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3550 General Atomics Ct.
San Diego, CA 92121
USA
Phone
(858) 455-3708
Website
www.viacyte.com
Email Address
[email protected]
Overview
ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
Profile
ViaCyte LinkedIn Company Profile
Social Media
ViaCyte Company Twitter Account
Company News
ViaCyte News
Facebook
ViaCyte on Facebook
YouTube
ViaCyte on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Michael Yang
  Michael Yang LinkedIn Profile  Michael Yang Twitter Account  Michael Yang News  Michael Yang on Facebook
Chief Financial Officer
Brittany Bradrick
  Brittany Bradrick LinkedIn Profile  Brittany Bradrick Twitter Account  Brittany Bradrick News  Brittany Bradrick on Facebook
Chief Medical Officer
Howard Foyt
  Howard Foyt LinkedIn Profile  Howard Foyt Twitter Account  Howard Foyt News  Howard Foyt on Facebook
Chief Scientific Officer
Kevin D'Amour
  Kevin D'Amour LinkedIn Profile  Kevin D'Amour Twitter Account  Kevin D'Amour News  Kevin D'Amour on Facebook
Chief Technical Officer
Steve White
  Steve White LinkedIn Profile  Steve White Twitter Account  Steve White News  Steve White on Facebook
Vice President
Manasi Jaiman
  Manasi Jaiman LinkedIn Profile  Manasi Jaiman Twitter Account  Manasi Jaiman News  Manasi Jaiman on Facebook
VP - Finance
Anne Sandan
  Anne Sandan LinkedIn Profile  Anne Sandan Twitter Account  Anne Sandan News  Anne Sandan on Facebook
VP - General Counsel
Liz Bui
  Liz Bui LinkedIn Profile  Liz Bui Twitter Account  Liz Bui News  Liz Bui on Facebook
VP - Regulatory Affairs
Steve Kradjian
  Steve Kradjian LinkedIn Profile  Steve Kradjian Twitter Account  Steve Kradjian News  Steve Kradjian on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/16/2007: Arkeia Software venture capital transaction
Next: 7/16/2007: BroadSoft venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.